Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million
GOTHENBURG, Sweden, May 25, 2021 - Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the “Company”) Board of Directors resolved on May 18, 2021, on an issue of shares of a maximum of 62,524,474 shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”). If the Rights Issue is fully subscribed, the Company will receive approximately SEK 400 million before transaction costs related to the Rights Issue. In connection with the Rights Issue, the Company publishes a prospectus which today has been approved and registered by